Trials / Completed
CompletedNCT03942263
A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation
KLIO - Non-interventional Multicenter Prospective and Retrospective Study to Describe Treatment Patterns and Disease Control in Patients With Classical Hodgkin's Lymphoma (cHL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) in Routine Clinical Practice in the Russian Federation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.
Detailed description
This is a non-interventional, prospective and retrospective study of participants with cHL and sALCL. The study will collect information on therapy and outcome of cHL and sALCL in real-life clinical practice. The study will enroll approximately 2000 participants. Based on the diagnosis of the disease, participants will be assigned to one of the following groups: * Newly Diagnosed and RR cHL Participants * Newly Diagnosed and RR sALCL Participants This multi-center trial will be conducted in Russia. The retrospective data will be collected for the participants with RR cHL or RR sALCL at the time of enrollment and for participants with RR cHL or RR sALCL within 3 years prior to inclusion in the study at Visit 1 (Baseline). The prospective data will be collected for a period of 2 years from Visit 1 (Baseline) to Visit 5 (Month 24, Final Visit), both for newly diagnosed participants with cHL or sALCL and participants with RR cHL or RR sALCL at the time of enrolment, and participants with RR cHL or RR sALCL within 3 years prior to inclusion in the study.
Conditions
Timeline
- Start date
- 2019-05-31
- Primary completion
- 2022-12-08
- Completion
- 2022-12-08
- First posted
- 2019-05-08
- Last updated
- 2024-07-15
Locations
50 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT03942263. Inclusion in this directory is not an endorsement.